Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded ...

Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI ® ” (brand name in China: “??? ® ”, ...

Hubert Dodds is currently an in-patient in Newcastle, but his family want him closer to home.

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and ...

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Nigel Thomas, 79, has dementia with Lewy bodies which is often misdiagnosed as Parkinson's.

Two Gold Coast patients have become the first in Queensland to receive new medications which doctors hope may offer a better ...

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders ...

Primary care physicians can prioritize conversations on heart disease, diabetes and cancer, and frame them around the need for whole-person health. Brain health deserves the same approach, and new ...

High blood pressure becomes more common after age 40, yet new research from The Irish Longitudinal Study on Ageing (TILDA) at Trinity College Dublin shows that many people in Ireland with hypertension ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...